# Mesenchymal Stem Cell Infusion for COVID-19 Infection

> **NCT04444271** · PHASE2 · UNKNOWN · sponsor: **Dr. Zaineb Akram** · enrollment: 20 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Mesenchymal stem cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04444271
- **Lead sponsor:** Dr. Zaineb Akram
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2020-08-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444271, "Mesenchymal Stem Cell Infusion for COVID-19 Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04444271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*